Digestive Health Institute, University Hospitals, Cleveland, OH, USA.
Cleveland Clinic Foundation, Cleveland, OH, USA.
Obes Surg. 2023 Dec;33(12):4065-4069. doi: 10.1007/s11695-023-06926-3. Epub 2023 Nov 16.
Obesity has a known association with certain types of malignancy, and we aimed to determine whether bariatric surgery has a protective effect against de novo obesity-associated cancer development in adult patients.
We performed a multi-center retrospective cohort studying utilizing TriNetX national database. Patients were identified utilizing ICD-10-CM coding, and propensity score matching was performed. We compared patients with obesity who underwent bariatric surgery to patients with obesity who did not undergo bariatric surgery.
We initially identified 60,285 patients in the bariatric surgery group and 1,570,440 patients in nonsurgical control group. After propensity score matching, we included 55,789 patients in each patient cohort. The cumulative incidence of de novo obesity-associated cancers at 10 years was 4.0% (2206 patients) in the bariatric surgery group and 8.9% (4,960 patients) in the nonsurgical control group (HR 0.482 [95% CI 0.459-0.507]). The bariatric surgery group had lower incidence proportions for de novo breast cancer (HR 0.753 [CI 0.678-0.836]), colon cancer (HR 0.638 [CI 0.541-0.752]), liver cancer (HR 0.370 [CI 0.345-0.396]), ovarian cancer (HR 0.654 [CI 0.531-0.806]), and endometrial cancer (HR 0.448 [CI 0.362-0.556]) when compared to the nonsurgical control group.
We noted that bariatric surgery is associated with a significantly lower cumulative incidence of de novo obesity-associated cancer compared to a nonsurgical matched control group. Incidence proportions of de novo breast, colon, liver, ovarian, and endometrial cancer were significantly lower in adult patients with obesity in the bariatric surgery group compared to the nonsurgical group.
肥胖与某些类型的恶性肿瘤有关,我们旨在确定减重手术是否对成年患者新发肥胖相关癌症的发展具有保护作用。
我们进行了一项利用 TriNetX 国家数据库的多中心回顾性队列研究。利用 ICD-10-CM 编码识别患者,并进行倾向评分匹配。我们比较了接受减重手术的肥胖患者和未接受减重手术的肥胖患者。
我们最初在减重手术组中确定了 60285 名患者,在非手术对照组中确定了 1570440 名患者。在进行倾向评分匹配后,我们在每个患者队列中纳入了 55789 名患者。在 10 年内新发肥胖相关癌症的累积发生率在减重手术组为 4.0%(2206 名患者),在非手术对照组为 8.9%(4960 名患者)(HR 0.482[95%CI 0.459-0.507])。与非手术对照组相比,减重手术组新发乳腺癌(HR 0.753[CI 0.678-0.836])、结肠癌(HR 0.638[CI 0.541-0.752])、肝癌(HR 0.370[CI 0.345-0.396])、卵巢癌(HR 0.654[CI 0.531-0.806])和子宫内膜癌(HR 0.448[CI 0.362-0.556])的发病比例较低。
我们注意到,与非手术匹配对照组相比,减重手术与新发肥胖相关癌症的累积发生率显著降低。与非手术组相比,肥胖患者的减重手术组新发乳腺癌、结肠癌、肝癌、卵巢癌和子宫内膜癌的发病比例明显较低。